1 1338 160 DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF A PHENYL BUTYRIC ACID DERIVATIVE, N-(4-CHLOROPHENYL)-4-PHENYLBUTANAMIDE: A HDAC6 INHIBITOR WITH ANTI-PROLIFERATIVE ACTIVITY ON CERVIX CANCER AND LEUKEMIA CELLS. BACKGROUND: THE EPIGENETIC REGULATION OF GENES IN CANCER COULD BE TARGETED BY INHIBITING HISTONE DEACETYLASE 6 (HDAC6), AN ENZYME INVOLVED IN SEVERAL TYPES OF CANCER SUCH AS LYMPHOMA, LEUKEMIA, OVARIAN CANCER, ETC. OBJECTIVE: THROUGH IN SILICO METHODS, A SET OF PHENYL BUTYRIC ACID DERIVATIVES WITH POSSIBLE HDAC6 INHIBITORY ACTIVITY WERE DESIGNED, RENDERING MONOPHENYLAMIDES AND BIPHENYLAMIDES USING TUBACIN (HDAC6 SELECTIVE INHIBITOR) AS REFERENCE. METHOD: THE TARGET COMPOUNDS WERE SUBMITTED TO THEORETICAL ADMET ANALYSES AND THEIR BINDING PROPERTIES ON DIFFERENT HDAC6 CONFORMERS WERE EVALUATED THROUGH DOCKING CALCULATIONS. RESULTS: THESE IN SILICO STUDIES ALLOWED US TO IDENTIFY A COMPOUND NAMED B-R2B. IN ORDER TO HAVE MORE INFORMATION ABOUT THE B-R2B BINDING RECOGNITION PROPERTIES ON HDAC6, THE B-R2B-HDAC6 COMPLEX WAS SUBMITTED THROUGH 100 NS-LONG MOLECULAR DYNAMICS (MD) SIMULATION COUPLED TO MMGBSA APPROACH, REVEALING THAT B-R2B IS LOCATED AT THE ENTRANCE OF HDAC6 ACTIVE POCKET, BLOCKING THE PASSAGE OF THE SUBSTRATE WITHOUT REACHING THE HDAC6 BINDING SITE. BASED ON THESE RESULTS, B-R2B WAS SYNTHESIZED, CHARACTERIZED AND BIOLOGICALLY TESTED. THE HDAC6 FLUOROMETRIC DRUG DISCOVERY KIT FLUOR-DE-LYS (ENZO LIFE SCIENCES INC.) WAS USED TO DETERMINE THE HDAC6 HUMAN INHIBITORY ACTIVITY (IC50 VALUE) OF B-R2B COMPOUND. IN ADDITION, B-R2B SHOW IC50 VALUES ON CANCER CELL LINES (HELA; IC50 = 72.6 MICROM), ACUTE MYELOID LEUKEMIA (THP-1; IC50 = 16.5 MICROM), HUMAN MAST LEUKEMIA (HMC; IC50 = 79.29 MICROM) AND CHRONIC MYELOGENOUS LEUKEMIA (KASUMI; IC50 = 101 MICROM). CONCLUSION: THESE RESULTS SHOW THAT B-R2B IS A HDAC6 INHIBITOR, SPECIFICALLY A NON-COMPETITIVE TYPE IN A SIMILAR WAY THAT TUBACIN DOES, ACCORDING TO MD SIMULATIONS. 2017 2 1572 24 DNA METHYLATION PATTERNS IN JUVENILE SYSTEMIC SCLEROSIS AND LOCALIZED SCLERODERMA. SCLERODERMA REFERS TO A GROUP OF CHRONIC FIBROTIC IMMUNE-MEDIATED DISEASES OF UNKNOWN ETIOLOGY. CHARACTERIZING EPIGENETIC CHANGES IN CHILDHOOD-ONSET SCLERODERMA, SYSTEMIC SCLEROSIS OR LOCALIZED SCLERODERMA, HAS NOT BEEN PREVIOUSLY PERFORMED. THE AIM OF THIS STUDY WAS TO ASSESS DNA METHYLATION DIFFERENCES AND SIMILARITIES BETWEEN JUVENILE SYSTEMIC SCLEROSIS (JSSC) AND JUVENILE LOCALIZED SCLERODERMA (JLS) COMPARED TO MATCHED HEALTHY CONTROLS. GENOME-WIDE DNA METHYLATION CHANGES IN PERIPHERAL BLOOD MONONUCLEAR CELL SAMPLES WERE ASSESSED USING THE METHYLATIONEPIC ARRAY FOLLOWED BY BIOINFORMATIC ANALYSIS AND LIMITED FUNCTIONAL ASSESSMENT. WE IDENTIFIED A TOTAL OF 105 AND 144 DIFFERENTIALLY METHYLATED SITES COMPARED TO HEALTHY CONTROLS IN JSSC AND JLS, RESPECTIVELY. THE MAJORITY OF DIFFERENTIALLY METHYLATED SITES AND GENES REPRESENTED WERE UNIQUE TO EITHER JSSC OR JLS SUGGESTING A DIFFERENT UNDERLYING EPIGENETIC PATTERN IN BOTH DISEASES. AMONG SHARED DIFFERENTIALLY METHYLATED GENES, METHYLATION LEVELS IN A CPG SITE IN FGFR2 CAN DISTINGUISH BETWEEN LS AND HEALTHY PBMCS WITH A HIGH ACCURACY. CANONICAL PATHWAY ANALYSIS REVEALED THAT INFLAMMATORY PATHWAYS WERE ENRICHED IN GENES DIFFERENTIALLY METHYLATED IN JSSC, INCLUDING STAT3, NF-KAPPAB, AND IL-15 PATHWAYS. IN CONTRAST, THE HIPPO SIGNALING PATHWAY WAS ENRICHED IN JLS. OUR DATA ALSO SUGGEST A POTENTIAL ROLE FOR NOTCH3 IN BOTH JSSC AND JLS, AND REVEALED A NUMBER OF TRANSCRIPTION FACTORS UNIQUE TO EACH OF THE TWO DISEASES. IN SUMMARY, OUR DATA REVEALED IMPORTANT INSIGHTS INTO JSSC AND JLS AND SUGGEST A POTENTIALLY NOVEL EPIGENETIC DIAGNOSTIC BIOMARKER FOR LS. 2021 3 1426 25 DIFFERENTIAL EFFECTS OF BUTYRIC ACID ON MOUSE SKIN TUMORIGENESIS. WE STUDIED THE EFFECTS OF BUTYRIC ACID (BA) ON MOUSE SKIN TUMORIGENESIS USING CHRONIC ANIMAL BIOASSAYS. TOPICAL APPLICATION OF BA IMMEDIATELY AFTER EACH TREATMENT WITH 12-0-TETRADECANOYLPHORBOL-13-ACETATE (TPA) PROMOTER-INHIBITED SKIN TUMORS. THE EFFECT WAS DEPENDENT ON THE DOSE OF BA APPLIED. BA SHOWED NO MARKED INHIBITORY EFFECT ON EITHER SKIN TUMOR INITIATION OR COMPLETE TUMORIGENESIS INDUCED BY DIMETHYLBENZANTHRACENE (DMBA). SINCE TUMOR PROMOTION REPORTEDLY INVOLVES EPIGENETIC EVENTS WHEREAS TUMOR INITIATION OR COMPLETE TUMORIGENESIS TAKES PLACE THROUGH GENETIC PATHWAYS, IT IS POSSIBLE THAT BA EXERTS ITS ANTITUMORIGENIC EFFECTS MAINLY BY ALTERING THE EPIGENETIC EVENTS RESPONSIBLE FOR TUMOR PROMOTION. THE RESULTS OF THE STUDY COULD FURTHER BE USED TO STUDY THE MECHANISM OF ACTION AND MODIFICATION OF ANTITUMORIGENIC EFFECTS OF BA IN COMBINATION WITH OTHER SUBSTANCES. 1997 4 6514 21 TRANSCRIPTIONAL ACTIVATION OF THE GP91PHOX NADPH OXIDASE SUBUNIT BY TPA IN HL-60 CELLS. THE EXPOSURE TO EPIGENETIC EFFECTORS CAPABLE OF INDUCING COPIOUS PRODUCTION OF REACTIVE OXYGEN SPECIES (ROS) HAS BEEN ASSOCIATED WITH CHRONIC INFLAMMATION, TUMOR INITIATION, AND PROMOTION. THE OBJECTIVE OF THIS STUDY WAS TO EXAMINE THE REGULATION OF GP91PHOX, THE CATALYTIC SUBUNIT OF THE NADPH OXIDASE, AND THE KINETICS OF ROS PRODUCTION IN PROMYELOCYTIC LEUKEMIA HL-60 CELLS INDUCED WITH 12-O-TETRADECONYLPHORBOL-13-ACETATE (TPA). THE TREATMENT OF HL-60 CELLS WITH TPA (0.1 MICROM) INDUCED CELLULAR DIFFERENTIATION, WHICH WAS FOLLOWED AFTER 48 H BY A TENFOLD INCREASE IN CHEMILUMINESCENCE FROM LUCIGENIN AND A 2.5-FOLD INCREASE IN THE INTRACELLULAR OXIDATION OF 2',7'-DICHOLOROFLUORESCIN (DCFH). WHEREAS HIGHER CONCENTRATIONS (1.0 MICROM) OF TPA DID NOT STIMULATE FURTHER ROS PRODUCTION, REPEATED STIMULATION WITH 0.1 MICROM TPA OF DIFFERENTIATED CELLS INDUCED A MODEST (1.2-FOLD) BUT RAPID (15 MIN) INCREASE IN CHEMILUMINESCENCE. IN CELLS TREATED WITH TPA, THE BURST IN ROS AT 48 H WAS PRECEDED BY ACCUMULATION AT 12 H OF GP91PHOX (8.8-FOLD) AND P47PHOX MRNA (THREEFOLD), WHEREAS UNTREATED CELLS CONTAINED STEADY-STATE LEVELS OF BOTH TRANSCRIPTS. TIME-COURSE EXPERIMENTS WITH ACTINOMYCIN D TO INHIBIT TRANSCRIPTION REVEALED THAT TPA DID NOT IMPROVE THE STABILITY OF GP91PHOX. IN TRANSIENT TRANSFECTIONS, LUCIFERASE REPORTER ACTIVITY DIRECTED FROM A 1.5-KB GP91PHOX PROMOTER FRAGMENT WAS ENHANCED THREEFOLD UPON TREATMENT WITH TPA FOR 24 H. WE CONCLUDE THAT TPA CAN COMMIT HL-60 CELLS TO DIFFERENTIATION AND ELICIT TRANSCRIPTION FROM THE PROXIMAL GP91PHOX PROMOTER. 2001 5 5674 25 SHARED GENETIC AND EPIGENETIC MECHANISMS BETWEEN CHRONIC PERIODONTITIS AND ORAL SQUAMOUS CELL CARCINOMA. OBJECTIVES: TO ANALYZE BIOINFORMATIC DATASETS FOR DETECTING GENETIC AND EPIGENETIC MECHANISMS SHARED BY CHRONIC PERIODONTITIS (CP) AND ORAL SQUAMOUS CELL CARCINOMA (OSCC). MATERIALS AND METHODS: DATASETS FROM GEO AND TCGA DATABASES REPORTING MRNAS, MIRNAS OR METHYLATION EXPRESSION IN HUMAN CP AND OSCC TISSUES WERE ANALYZED. DIFFERENTIAL EXPRESSION, FUNCTIONAL ENRICHMENT AND PROTEIN-PROTEIN INTERACTION (PPI) NETWORK ANALYSES WERE PERFORMED. DIFFERENTIALLY EXPRESSED MIRNAS (DEMIRNAS) AND GENES (DEG) IN CP AND OSCC WERE DETERMINED. DEMIRNA-TARGET AND DEMIRNA-DEG NETWORKS WERE CONSTRUCTED. DIRECTLY AND INDIRECTLY INTERACTING CROSS-TALK GENES WERE SCREENED, AND THEIR PREDICTION ACCURACY AND ASSOCIATION WITH OSCC PROGNOSIS WAS DETERMINED. RESULTS: 3 DE-MIRNAS (MIR-375, MIR-3609 AND MIR-3652) EXPRESSED IN BOTH CP AND OSCC CRITICALLY REGULATED MOST DEGS. AMONG 12 DIRECTLY INTERACTING CROSS-TALK GENES, NCAPH WAS SIGNIFICANTLY RELATED WITH THE PROGNOSIS OF OSCC. NR2F2 HAD HIGHEST DIFFERENTIAL EXPRESSION IN CP AND OSCC. AMONG 4 CROSS-TALK GENES (FN1, MPPED1, NDEL1, AND NR2F2) DIFFERENTIALLY EXPRESSED IN CP, 3 (FN1, MPPED1, NDEL1) WERE ALSO EXPRESSED IN OSCC. AMONG 12 INDIRECTLY INTERACTING CROSS-TALK GENES DIFFERENTIALLY EXPRESSED IN OSCC, 3 GENES (CDCA8, HIST1H3J, AND RAD51) WERE SIGNIFICANTLY RELATED TO ITS PROGNOSIS. SIGNIFICANT PATHWAYS INVOLVED IN CP AND OSCC INCLUDED: CHEMOKINE RECEPTORS, CLASS I PI3K SIGNALING EVENTS, EPITHELIAL-TO-MESENCHYMAL TRANSITION AND SIGNALING EVENTS BY VEGFR1 AND VEGFR2, EGF RECEPTOR (ERBB1). CONCLUSION: BIOINFORMATIC ANALYSIS OF AVAILABLE DATASETS IMPLICATED 1 DIRECTLY INTERACTING CROSS-TALK GENE (NCAPH), 4 INDIRECTLY INTERACTING CROSS-TALK GENES (NCAPH, NR2F2, FN1, AND MPPED1) AND 3 DE-MIRNAS (HSA-MIR-375, MIR-3609 AND MIR-3652) AS SHARED GENETIC AND EPIGENETIC EXPRESSION PATTERNS BETWEEN CP AND OSCC. 2018 6 6586 32 TUBASTATIN, A SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR SHOWS ANTI-INFLAMMATORY AND ANTI-RHEUMATIC EFFECTS. EPIGENETIC MODIFICATIONS REPRESENT A PROMISING NEW APPROACH TO MODULATE CELL FUNCTIONS AS OBSERVED IN AUTOIMMUNE DISEASES. EMERGING EVIDENCE SUGGESTS THE UTILITY OF HDAC INHIBITORS IN THE TREATMENT OF CHRONIC IMMUNE AND INFLAMMATORY DISORDERS. HOWEVER, CLASS AND ISOFORM SELECTIVE INHIBITION OF HDAC IS CURRENTLY FAVORED AS IT LIMITS THE TOXICITY THAT HAS BEEN OBSERVED WITH PAN-HDAC INHIBITORS. HDAC6, A MEMBER OF THE HDAC FAMILY, WHOSE MAJOR SUBSTRATE IS ALPHA-TUBULIN, IS BEING INCREASINGLY IMPLICATED IN THE PATHOGENESIS OF INFLAMMATORY DISORDERS. THE PRESENT STUDY WAS CARRIED OUT TO STUDY THE POTENTIAL ANTI-INFLAMMATORY AND ANTI-RHEUMATIC EFFECTS OF HDAC6 SELECTIVE INHIBITOR TUBASTATIN. TUBASTATIN, A POTENT HUMAN HDAC6 INHIBITOR WITH AN IC50 OF 11 NM SHOWED SIGNIFICANT INHIBITION OF TNF-ALPHA AND IL-6 IN LPS STIMULATED HUMAN THP-1 MACROPHAGES WITH AN IC50 OF 272 NM AND 712 NM RESPECTIVELY. ADDITIONALLY, TUBASTATIN INHIBITED NITRIC OXIDE (NO) SECRETION IN MURINE RAW 264.7 MACROPHAGES DOSE DEPENDENTLY WITH AN IC50 OF 4.2 MUM AND INDUCED ALPHA-TUBULIN HYPERACETYLATION CORRESPONDING TO HDAC6 INHIBITION IN THP-1 CELLS WITHOUT AFFECTING THE CELL VIABILITY. TUBASTATIN SHOWED SIGNIFICANT INHIBITION OF PAW VOLUME AT 30 MG/KG I.P. IN A FREUND'S COMPLETE ADJUVANT (FCA) INDUCED ANIMAL MODEL OF INFLAMMATION. THE DISEASE MODIFYING ACTIVITY OF TUBASTATIN WAS ALSO EVIDENT IN COLLAGEN INDUCED ARTHRITIS DBA1 MOUSE MODEL AT 30 MG/KG I.P. THE SIGNIFICANT ATTENUATION OF CLINICAL SCORES (~70%) BY TUBASTATIN WAS CONFIRMED HISTOPATHOLOGICALLY AND WAS FOUND COMPARABLE TO DEXAMETHASONE (~90% INHIBITION OF CLINICAL SCORES). TUBASTATIN SHOWED SIGNIFICANT INHIBITION OF IL-6 IN PAW TISSUES OF ARTHRITIC MICE. THE PRESENT WORK HAS DEMONSTRATED ANTI-INFLAMMATORY AND ANTIRHEUMATIC EFFECTS OF A SELECTIVE HDAC6 INHIBITOR TUBASTATIN. 2013 7 4240 19 METHYLATION QUANTITATIVE TRAIT LOCUS ANALYSIS OF CHRONIC POSTSURGICAL PAIN UNCOVERS EPIGENETIC MEDIATORS OF GENETIC RISK. BACKGROUND: OVERLAP OF PATHWAYS ENRICHED BY SINGLE NUCLEOTIDE POLYMORPHISMS AND DNA-METHYLATION UNDERLYING CHRONIC POSTSURGICAL PAIN (CPSP), PROMPTED PILOT STUDY OF CPSP-ASSOCIATED METHYLATION QUANTITATIVE TRAIT LOCI (MEQTL). MATERIALS & METHODS: CHILDREN UNDERGOING SPINE-FUSION WERE RECRUITED PROSPECTIVELY. LOGISTIC-REGRESSION FOR GENOME- AND EPIGENOME-WIDE CPSP ASSOCIATION AND DNA-METHYLATION-SINGLE NUCLEOTIDE POLYMORPHISM ASSOCIATION/MEDIATION ANALYSES TO IDENTIFY MEQTLS WERE FOLLOWED BY FUNCTIONAL GENOMICS ANALYSES. RESULTS: CPSP (N = 20/58) AND NON-CPSP GROUPS DIFFERED IN PAIN-MEASURES. OF 2753 MEQTLS, DNA-METHYLATION AT 127 CYTOSINE-GUANINE DINUCLEOTIDES MEDIATED ASSOCIATION OF 470 MEQTLS WITH CPSP (P < 0.05). AT PARK16 LOCUS, CPSP RISK MEQTLS WERE ASSOCIATED WITH DECREASED DNA-METHYLATION AT RAB7L1 AND INCREASED DNA-METHYLATION AT PM20D1. CORRESPONDING RAB7L1/PM20D1 BLOOD EQTLS (GTEX) AND CYTOSINE-GUANINE DINUCLEOTIDE-LOCI ENRICHMENT FOR HISTONE MARKS, TRANSCRIPTION FACTOR BINDING SITES AND ATAC-SEQ PEAKS SUGGEST ALTERED TRANSCRIPTION FACTOR-BINDING. CONCLUSION: CPSP-ASSOCIATED MEQTLS INDICATE EPIGENETIC MECHANISMS MEDIATE GENETIC RISK. CLINICAL TRIAL REGISTRATION: NCT01839461, NCT01731873 (CLINICALTRIALS.GOV). 2021 8 1496 22 DNA IS HYPOMETHYLATED IN CIRCADIAN MANIFESTATIONS OF BRUXISM. OBJECTIVE: THE AIM OF THIS STUDY WAS TO COMPARE THE GLOBAL DNA METHYLATION LEVELS IN PATIENTS UNDER BRUXISM TREATMENT AND A CONTROL GROUP. METHODS: SUBJECTS UNDERGOING BRUXISM TREATMENT WERE CLASSIFIED IN AWAKE BRUXISM (42 PATIENTS), SLEEP BRUXISM (32 PATIENTS) AND BOTH CONDITIONS (42 PATIENTS). THE CONTROL GROUP INCLUDED 42 INDIVIDUALS. A COLORIMETRIC ASSAY (METHYLFLASH METHYLATED DNA 5-MC QUANTIFICATION KIT, EPIGENETIC GROUP INC., NY, USA) WAS USED TO DETERMINE THE GLOBAL DNA METHYLATION LEVELS. RESULTS: STATISTICALLY SIGNIFICANT DIFFERENCES WERE FOUND IN AMOUNTS OF METHYLATED DNA IN ALL CIRCADIAN MANIFESTATIONS OF BRUXISM COMPARED WITH A CONTROL GROUP (SLEEP BRUXISM = 0.95% +/- 2.02%; AWAKE BRUXISM = 0.87% +/- 2.1%; SLEEP AND AWAKE BRUXISM = 0.17% +/- 0.25%; CONTROL = 1.69% +/- 1.6%; KRUSKAL-WALLIS TEST [P = .0001] FOLLOWED BY DUNN'S TEST [P < .05]). CONCLUSION: PATIENTS UNDERGOING BRUXISM TREATMENT EXHIBITED HYPOMETHYLATED DNA LEVELS WHEN COMPARED TO CONTROL GROUP. OUR RESULTS SUGGEST THAT DNA HYPOMETHYLATION MIGHT BE A NOVEL AETIOLOGIC FACTOR IN BRUXISM AETIOLOGY. FURTHER RESEARCHES MUST BE PERFORMED EXPLORING THE ROLE OF EPIGENETICS MODIFICATIONS IN CIRCADIAN MANIFESTATIONS OF BRUXISM. 2018 9 1422 30 DIFFERENTIAL CPG DNA METHYLATION OF PERIPHERAL B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES IN IGG4-RELATED DISEASE. OBJECTIVES: IMMUNOGLOBULIN-G4-RELATED DISEASE (IGG4-RD) IS A DISTINCT SYSTEMIC AUTOIMMUNE-MEDIATED DISEASE MANIFESTING AS CHRONIC INFLAMMATION AND TISSUE FIBROSIS. SINCE THE ROLE OF DNA METHYLATION IN THE PATHOGENESIS OF IGG4-RD IS STILL UNCLEAR, WE CONDUCT THIS STUDY TO INVESTIGATE EPIGENETIC MODIFICATIONS IN IGG4-RD. METHODS: A GENOME-WIDE DNA METHYLATION STUDY WAS CONDUCTED WITH B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES FROM IGG4-RD PATIENTS AND MATCHED CONTROLS BY USING THE ILLUMINA HUMANMETHYLATION 850K BEADCHIP. WE FURTHER PERFORMED PYROSEQUENCING AND IMMUNOHISTOCHEMISTRY ASSAYS TO VALIDATE THE METHYLATION STATUS OF SOME TARGETS OF INTEREST. RESULTS: WE IDENTIFIED DIFFERENTIALLY METHYLATED CPG SITES INCLUDING 44 HYPOMETHYLATED AND 166 HYPERMETHYLATED DIFFERENTIALLY METHYLATED PROBES (DMPS) IN B CELLS AND 260 HYPOMETHYLATED AND 112 HYPERMETHYLATED DMPS IN CD4(+) T CELLS FROM 10 IGG4-RD PATIENTS COMPARED WITH 10 HEALTHY CONTROLS. WE ALSO IDENTIFIED 36945 HYPOMETHYLATED AND 78380 HYPERMETHYLATED DMPS IN SALIVARY GLAND TISSUES OF 4 IGG4-RD PATIENTS COMPARED WITH 4 CONTROLS. DPM2 (CG21181453), IQCK (CG10266221), AND ABCC13 (CG05699681, CG04985582) WERE HYPERMETHYLATED AND MBP (CG18455083) WAS HYPOMETHYLATED IN B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES OF IGG4-RD PATIENTS. WE ALSO OBSERVED THE HYPOMETHYLATED HLA-DQB2 IN CD4(+) T CELLS FROM IGG4-RD PATIENTS. KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG) PATHWAY ANALYSIS OF DMPS IN SALIVARY GLAND TISSUES OF IGG4-RD PATIENTS REVEALED ENRICHMENT OF PATHWAYS INVOLVED IN THE REGULATION OF IMMUNE CELL RESPONSES AND FIBROSIS. CONCLUSION: THIS IS THE FIRST DNA METHYLATION STUDY IN PERIPHERAL B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES FROM IGG4-RD PATIENTS. OUR FINDINGS HIGHLIGHTED THE ROLE OF EPIGENETIC MODIFICATION OF DNA METHYLATION AND IDENTIFIED SEVERAL GENES AND PATHWAYS POSSIBLY INVOLVED IN IGG4-RD PATHOGENESIS. 2023 10 2811 26 FGFR2-RELATED PATHOGENESIS AND FGFR2-TARGETED THERAPEUTICS (REVIEW). FGFR2 GENE AT HUMAN CHROMOSOME 10Q26 ENCODES FGFR2B AND FGFR2C ISOFORMS FUNCTIONING AS FGF RECEPTORS WITH DISTINCT EXPRESSION DOMAIN AND LIGAND SPECIFICITY. FGFR2 PLAYS ONCOGENIC AND ANTI-ONCOGENIC ROLES IN A CONTEXT-DEPENDENT MANNER. SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) WITHIN INTRON 2 OF FGFR2 GENE ARE ASSOCIATED WITH BREAST CANCER THROUGH ALLELIC FGFR2 UPREGULATION. MISSENSE MUTATIONS OR COPY NUMBER GAINS OF FGFR2 GENE OCCUR IN BREAST CANCER AND GASTRIC CANCER TO ACTIVATE FGFR2 SIGNALING. ABERRANT FGFR2 SIGNALING ACTIVATION INDUCES PROLIFERATION AND SURVIVAL OF TUMOR CELLS. THE CLASS SWITCH FROM FGFR2B TO FGFR2C OCCURS DURING PROGRESSION OF PROSTATE CANCER AND BLADDER CANCER BECAUSE OF SPLICEOSOME DYSREGULATION. IN ADDITION, EPIDERMAL FGFR2B KNOCKOUT MICE SHOW INCREASED SENSITIVITY TO CHEMICAL CARCINOGENESIS PARTLY DUE TO THE FAILURE OF NFE2L2 (NRF2)-MEDIATED DETOXIFICATION OF REACTIVE OXYGEN SPECIES (ROS). LOSS OF FGFR2B SIGNALING INDUCES EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) AND UNRULY ROS. FGFR2 SIGNALING DYSREGULATION DUE TO THE ACCUMULATION OF EPIGENETIC MODIFICATIONS AND GENETIC ALTERATIONS DURING CHRONIC INFLAMMATION, SMOKING, INCREASED CALORIC UPTAKE, AND DECREASED EXERCISE LEADS TO CARCINOGENESIS. PD173074, SU5402, AZD2171, AND KI23057 ARE SMALL-MOLECULE FGFR INHIBITORS. HUMAN ANTIBODY, PEPTIDE MIMETIC, RNA APTAMER, SIRNA, AND SYNTHETIC MICRORNA (MIRNA) ARE EMERGING TECHNOLOGIES TO BE APPLIED FOR CANCER THERAPEUTICS TARGETED TO FGFR2. BECAUSE NOVEL SEQUENCE TECHNOLOGY AND PETA-SCALE SUPER-COMPUTER ARE OPENING UP THE SEQUENCE ERA FOLLOWING THE GENOME ERA, PERSONALIZED MEDICINE PRESCRIBING TARGETED DRUGS BASED ON GERMLINE AND/OR SOMATIC GENOMIC INFORMATION IS COMING REALITY. APPLICATION OF FGFR2 INHIBITORS FOR CANCER TREATMENT IN PATIENTS WITH FGFR2 MUTATION OR GENE AMPLIFICATION IS BENEFICIAL; HOWEVER, THAT FOR CANCER PREVENTION IN PEOPLE WITH FGFR2 RISK ALLELE MIGHT BE DISADVANTAGEOUS DUE TO THE IMPEDIMENT OF A CYTOPROTECTIVE MECHANISM AGAINST OXIDATIVE STRESS. 2009 11 2127 30 EPIGENETIC INACTIVATION OF MIR-9 FAMILY MICRORNAS IN CHRONIC LYMPHOCYTIC LEUKEMIA--IMPLICATIONS ON CONSTITUTIVE ACTIVATION OF NFKAPPAB PATHWAY. BACKGROUND: THE MIR-9 FAMILY MICRORNAS HAVE BEEN IDENTIFIED AS A TUMOR SUPPRESSOR MIRNA IN CANCERS. WE POSTULATED THAT MIR-9-1, MIR-9-2 AND MIR-9-3 MIGHT BE INACTIVATED BY DNA HYPERMETHYLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). METHODS: METHYLATION OF MIR-9-1, MIR-9-2 AND MIR-9-3 WAS STUDIED IN EIGHT NORMAL CONTROLS INCLUDING NORMAL BONE MARROW, BUFFY COAT, AND CD19-SORTED PERIPHERAL BLOOD B-CELLS FROM HEALTHY INDIVIDUALS, SEVEN CLL CELL LINES, AND SEVENTY-EIGHT DIAGNOSTIC CLL SAMPLES BY METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION. RESULTS: THE PROMOTERS OF MIR-9-3 AND MIR-9-1 WERE BOTH UNMETHYLATED IN NORMAL CONTROLS, BUT METHYLATED IN FIVE (71.4%) AND ONE OF SEVEN CLL CELL LINES RESPECTIVELY. HOWEVER, MIR-9-2 PROMOTER WAS METHYLATED IN NORMAL CONTROLS INCLUDING CD19 + VE B-CELLS, HENCE SUGGESTIVE OF A TISSUE-SPECIFIC BUT NOT TUMOR-SPECIFIC METHYLATION, AND THUS NOT FURTHER STUDIED. DIFFERENT MSP STATUSES OF MIR-9-3, INCLUDING COMPLETE METHYLATION, PARTIAL METHYLATION, AND COMPLETE UNMETHYLATION, WERE VERIFIED BY QUANTITATIVE BISULFITE METHYLATION ANALYSIS. 5-AZA-2'-DEOXYCYTIDINE TREATMENT RESULTED IN MIR-9-3 PROMOTER DEMETHYLATION AND RE-EXPRESSION OF PRI-MIR-9-3 IN I83-E95 AND WAC3CD5+ CELLS, WHICH WERE HOMOZYGOUSLY METHYLATED FOR MIR-9-3. MOREOVER, OVEREXPRESSION OF MIR-9 LED TO SUPPRESSED CELL PROLIFERATION AND ENHANCED APOPTOSIS TOGETHER WITH DOWNREGULATION OF NFKAPPAB1 IN I83-E95 CELLS, SUPPORTING A TUMOR SUPPRESSOR ROLE OF MIR-9-3 IN CLL. IN PRIMARY CLL SAMPLES, MIR-9-3 WAS DETECTED IN 17% AND MIR-9-1 METHYLATION IN NONE OF THE PATIENTS AT DIAGNOSIS. MOREOVER, MIR-9-3 METHYLATION WAS ASSOCIATED WITH ADVANCED RAI STAGE (>/= STAGE 2) (P = 0.04). CONCLUSIONS: OF THE MIR-9 FAMILY, MIR-9-3 IS A TUMOR SUPPRESSOR MIRNA RELATIVELY FREQUENTLY METHYLATED, AND HENCE SILENCED IN CLL; WHEREAS MIR-9-1 METHYLATION IS RARE IN CLL. THE ROLE OF MIR-9-3 METHYLATION IN THE CONSTITUTIVE ACTIVATION OF NFKAPPAB SIGNALING PATHWAY IN CLL WARRANTS FURTHER STUDY. 2013 12 4697 34 NF-KAPPAB UPREGULATION THROUGH EPIGENETIC SILENCING OF LDOC1 DRIVES TUMOR BIOLOGY AND SPECIFIC IMMUNOPHENOTYPE IN GROUP A EPENDYMOMA. BACKGROUND: INFLAMMATION HAS BEEN IDENTIFIED AS A HALLMARK OF HIGH-RISK GROUP A (GPA) EPENDYMOMA (EPN). CHRONIC INTERLEUKIN (IL)-6 SECRETION FROM GPA TUMORS DRIVES AN IMMUNE SUPPRESSIVE PHENOTYPE BY POLARIZING INFILTRATING MONOCYTES. THIS STUDY DETERMINES THE MECHANISM BY WHICH IL-6 IS DYSREGULATED IN GPA EPN. METHODS: TWENTY PEDIATRIC GPA AND 21 PEDIATRIC GROUP B (GPB) EPN HAD GENE SET ENRICHMENT ANALYSIS FOR MSIGDB HALLMARK GENE SETS PERFORMED. PROTEIN AND RNA FROM PATIENTS AND CELL LINES WERE USED TO VALIDATE TRANSCRIPTOMIC FINDINGS. GPA CELL LINES 811 AND 928 WERE USED FOR IN VITRO EXPERIMENTS PERFORMED IN THIS STUDY. RESULTS: THE NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) PATHWAY IS A MASTER REGULATOR OF IL-6 AND A SIGNALING PATHWAY ENRICHED IN GPA COMPARED WITH GPB EPN. KNOCKDOWN OF NF-KAPPAB LED TO SIGNIFICANT DOWNREGULATION OF IL-6 IN 811 AND 928. NF-KAPPAB ACTIVATION WAS INDEPENDENT OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) STIMULATION IN BOTH CELL LINES, SUGGESTING THAT NF-KAPPAB HYPERACTIVATION IS MEDIATED THROUGH AN ALTERNATIVE MECHANISM. LEUCINE ZIPPER DOWNREGULATED IN CANCER 1 (LDOC1) IS A KNOWN TRANSCRIPTIONAL REPRESSOR OF NF-KAPPAB. IN MANY CANCERS, LDOC1 PROMOTER IS METHYLATED, WHICH INHIBITS GENE TRANSCRIPTION. WE FOUND DECREASED LDOC1 GENE EXPRESSION IN GPA COMPARED WITH GPB EPN, AND IN OTHER PEDIATRIC BRAIN TUMORS. EPN CELLS TREATED WITH 5AZA-DC, DEMETHYLATED LDOC1 REGULATORY REGIONS, UPREGULATED LDOC1 EXPRESSION, AND CONCOMITANTLY DECREASED IL-6 SECRETION. STABLE KNOCKDOWN OF LDOC1 IN EPN CELL LINES RESULTED IN A SIGNIFICANT INCREASE IN GENE TRANSCRIPTION OF V-REL AVIAN RETICULOENDOTHELIOSIS VIRAL ONCOGENE HOMOLOG A, WHICH CORRELATED TO AN INCREASE IN NF-KAPPAB TARGET GENES. CONCLUSION: THESE RESULTS SUGGEST THAT EPIGENETIC SILENCING OF LDOC1 IN GPA EPN REGULATES TUMOR BIOLOGY AND DRIVES INFLAMMATORY IMMUNE PHENOTYPE. 2017 13 3753 23 INTEGRATED ANALYSIS OF GENE EXPRESSION AND METHYLATION DATA TO IDENTIFY POTENTIAL BIOMARKERS RELATED TO ATHEROSCLEROSIS ONSET. ATHEROSCLEROSIS IS A KIND OF CHRONIC INFLAMMATORY CARDIOVASCULAR DISEASE. EPIGENETIC REGULATION PLAYS A CRUCIAL ROLE IN ATHEROSCLEROSIS. OUR STUDY WAS AIMED AT FINDING POTENTIAL BIOMARKERS ASSOCIATED WITH THE OCCURRENCE OF ATHEROSCLEROSIS. TWO DATASETS WERE DOWNLOADED FROM THE GENE EXPRESSION OMNIBUS (GEO) DATABASE. THE EPIGENOME-WIDE ASSOCIATION STUDY (EWAS) ANALYSIS WAS PERFORMED ON METHYLATION DATA USING CPGASSOC PACKAGE. THE DIFFERENTIAL EXPRESSION ANALYSIS WAS CONDUCTED ON MRNA DATA USING LIMMA PACKAGE. THE GO (GENE ONTOLOGY) AND KEGG (KYOTO ENCYCLOPEDIA OF GENES AND GENOMES) FUNCTIONAL ENRICHMENT WAS DONE IN CLUSTERPROFILER PACKAGE. FINALLY, THE LOGISTIC REGRESSION MODEL WAS CONSTRUCTED USING GENERALIZED LINEAR MODEL (GLM) FUNCTION. BETWEEN ATHEROSCLEROTIC VS. NONATHEROSCLEROTIC SAMPLES, TOTALLY 4980 CYTOSINE-PHOSPHATE-GUANINE (CPG) SITES (ANNOTATED TO 2860 GENES) AND 132 DIFFERENTIALLY EXPRESSED GENES (DEGS) RELATED TO ATHEROSCLEROSIS WERE IDENTIFIED. THE ANNOTATED 2860 GENES AND 132 DEGS WERE SIGNIFICANTLY ENRICHED IN 9 AND 4 KEGG PATHWAYS AND 289 AND 132 GO TERMS, RESPECTIVELY. AFTER CROSS-ANALYSIS, 6 CRUCIAL CPG SITES WERE SCREENED TO BUILD THE MODEL, INCLUDING CG01187920, CG03422911, CG08018825, CG10967350, CG14473924, AND CG25313204. THE DIAGNOSTIC MODEL COULD RELIABLY SEPARATE THE ATHEROSCLEROSIS SAMPLES FROM NONATHEROSCLEROTIC SAMPLES. IN CONCLUSION, THE 6 CPG SITES ARE PROBABLY POTENTIAL DIAGNOSTIC BIOMARKERS FOR ATHEROSCLEROSIS, INCLUDING CG01187920, CG03422911, CG08018825, CG10967350, CG14473924, AND CG25313204. 2022 14 3453 21 HYPOMETHYLATED UBIQUITIN-CONJUGATING ENZYME2 Q1 (UBE2Q1) GENE PROMOTER IN THE SERUM IS A PROMISING BIOMARKER FOR HEPATITIS B VIRUS-ASSOCIATED HEPATOCELLULAR CARCINOMA. ABERRANT DNA METHYLATION, WHICH CAN BE DETECTED IN CIRCULATING CELL-FREE DNA (CFDNA), IS ONE OF THE MAJOR EPIGENETIC ALTERATIONS IN HEPATOCELLULAR CARCINOMA (HCC). UBE2Q1, A PUTATIVE MEMBER OF THE UBIQUITIN-CONJUGATING ENZYME FAMILY, MIGHT PLAY SUBSTANTIAL ROLES IN TUMORIGENESIS. HOWEVER, THE METHYLATION STATUS OF THE UBE2Q1 GENE IN HCC REMAINS UNKNOWN. WE AIMED TO DETERMINE THE METHYLATION STATUS OF THE UBE2Q1 GENE PROMOTER AND TO EVALUATE ITS POTENTIAL CLINICAL SIGNIFICANCE FOR HCC DETECTION. THE METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP) ASSAY WAS USED TO DETECT THE UBE2Q1 GENE METHYLATION STATUS IN SERUM SAMPLES FROM 80 PATIENTS WITH HEPATITIS B VIRUS (HBV)-RELATED HCC, 40 PATIENTS WITH LIVER CIRRHOSIS (LC), 40 PATIENTS WITH CHRONIC HEPATITIS B (CHB), AND 20 HEALTHY CONTROLS (HCS). SIGNIFICANTLY LOWER METHYLATION FREQUENCIES WERE DETECTED IN HCC PATIENTS (33.75%) COMPARED WITH LC PATIENTS (55.00%, P = 0.026) AND CHB PATIENTS (60.00%, P = 0.006) AND HCS (65.00%, P = 0.011). HYPOMETHYLATION OF THE UBE2Q1 GENE WAS NEGATIVELY ASSOCIATED WITH THE TUMOR NODE METASTASIS STAGE (R(S) = -0.30, P = 0.008). THE UBE2Q1 GENE METHYLATION STATUS COMBINED WITH ALPHA FETOPROTEIN USING CUT-OFF POINTS OF 20, 200 AND 400 NG/ML SHOWED SENSITIVITY AND SPECIFICITY VALUES OF 58.8% AND 75.0%, 53.8% AND 87.5%, AND 37.5% AND 88.7%, RESPECTIVELY, AND YIELDED A SIGNIFICANTLY INCREASED AREA UNDER THE ROC CURVE (0.720, 0.760 AND 0.694, RESPECTIVELY) FOR DISCRIMINATING HCC FROM LC AND CHB. OUR STUDY RESULTS SUGGEST THAT HYPOMETHYLATION OF THE UBE2Q1 GENE PROMOTER IS A POTENTIAL BIOMARKER FOR DETECTING HBV-ASSOCIATED HCC. 2017 15 671 36 BOTHROPS MOOJENI L-AMINO ACID OXIDASE INDUCES APOPTOSIS AND EPIGENETIC MODULATION ON BCR-ABL(+) CELLS. BACKGROUND: RESISTANCE TO APOPTOSIS IN CHRONIC MYELOID LEUKEMIA (CML) IS ASSOCIATED WITH CONSTITUTIVE TYROSINE KINASE ACTIVITY OF THE BCR-ABL ONCOPROTEIN. THE DEREGULATED EXPRESSION OF APOPTOSIS-RELATED GENES AND ALTERATION IN EPIGENETIC MACHINERY MAY ALSO CONTRIBUTE TO APOPTOSIS RESISTANCE IN CML. TYROSINE KINASE INHIBITORS TARGET THE BCR-ABL ONCOPROTEIN AND ARE USED IN CML TREATMENT. THE RESISTANCE OF CML PATIENTS TO TYROSINE KINASE INHIBITORS HAS GUIDED THE SEARCH FOR NEW COMPOUNDS THAT MAY INDUCE APOPTOSIS IN BCR-ABL(+) LEUKEMIC CELLS AND IMPROVE THE DISEASE TREATMENT. METHODS: IN THE PRESENT STUDY, WE INVESTIGATED WHETHER THE L-AMINO ACID OXIDASE ISOLATED FROM BOTHROPS MOOJENI SNAKE VENOM (BMOOLAAO-I) (I) WAS CYTOTOXIC TO BCR-ABL(+) CELL LINES (HL-60.BCR-ABL, K562-S, AND K562-R), HL-60 (ACUTE PROMYELOCYTIC LEUKEMIA) CELLS, THE NON-TUMOR CELL LINE HEK-293, AND PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC); AND (II) AFFECTED EPIGENETIC MECHANISMS, INCLUDING DNA METHYLATION AND MICRORNAS EXPRESSION IN VITRO. RESULTS: BMOOLAAO-I INDUCED ROS PRODUCTION, APOPTOSIS, AND DIFFERENTIAL DNA METHYLATION PATTERN OF REGULATORY APOPTOSIS GENES. THE TOXIN UPREGULATED EXPRESSION OF THE PRO-APOPTOTIC GENES BID AND FADD AND DOWNREGULATED DFFA EXPRESSION IN LEUKEMIC CELL LINES, AS WELL AS INCREASED MIR-16 EXPRESSION - WHOSE MAJOR PREDICTED TARGET IS THE ANTI-APOPTOTIC GENE BCL2 - IN BCR-ABL(+) CELLS. CONCLUSION: BMOOLAAO-I EXERTS SELECTIVE ANTITUMOR ACTION MEDIATED BY H(2)O(2) RELEASE AND INDUCES APOPTOSIS, AND ALTERATIONS IN EPIGENETIC MECHANISMS. THESE RESULTS SUPPORT FUTURE INVESTIGATIONS ON THE EFFECT OF BMOOLAAO-I ON IN VIVO MODELS TO DETERMINE ITS POTENTIAL IN CML THERAPY. 2020 16 6832 26 [HYPOMETHYLATION OF TNF-ALPHA GENE PROMOTER IN THE PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B LIVER FAILURE]. OBJECTIVE: THE PRESENT STUDY WAS DESIGNED TO INVESTIGATE THE POSSIBLE EPIGENETIC ALTERATION IN THE PROMOTER OF TNF-ALPHA IN THE PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B LIVER FAILURE (ACHBLF). METHODS: THE METHYLATION OF TNF-ALPHA PROMOTER IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) WAS MEASURED BY METHYLATION SPECIFIC PCR (MSP). THE LEVEL OF SERUM TNF-ALPHA WAS DETERMINED BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA). MODEL FOR END-STAGE LIVER DISEASE (MELD) WAS PERFORMED FOR THE EVALUATION OF LIVER FAILURE. RESULTS: THE SERUM LEVEL OF TNF-ALPHA IN PATIENTS WITH ACHBLF(44.9260 +/- 26.48523) WAS HIGHER THAN THAT IN CHB (18.92505 +/- 9.04461) AND HEALTHY CONTROLS (11.9172 +/- 5.04612) (P < 0.05). MOREOVER, THE SERUM TNF-ALPHA LEVEL WAS SIGNIFICANTLY DECREASED IN METHYLATION GROUP AS COMPARED TO UNMETHYLAITON GROUP IN PATIENTS WITH ACHBLF (P < 0.05). MELD WAS NOT SIGNIFICANTLY DIFFERENT BETWEEN METHYLATED AND UNMETHYLATED GROUP OF ACHBLF PATIENTS (P > 0.05). IN ADDITION, THE SERUM LEVEL OF TNF-ALPHA WAS FOUND TO BE POSITIVELY CORRELATED WITH SERUM TOTAL BILIRUBIN (R = 0.891, P < 0.01) AND MELD SCORE (R = 0.792, P < 0.01), BUT TO BE NEGATIVELY CORRELATED WITH PROTHROMBIN ACTIVITY (R = - 0.511, P < 0.05) IN PATIENTS WITH ACHBLF. CONCLUSION: THE TNF-ALPHA METHYLATION PATTEN IS STABLE FOR THE LIVER FAILURE, SUGGESTING THE EFFECT OF ENVIRONMENT ON METHYLATION. 2011 17 1592 29 DNA METHYLATION PROFILING OF GENOMIC DNA ISOLATED FROM URINE IN DIABETIC CHRONIC KIDNEY DISEASE: A PILOT STUDY. AIM: TO CHARACTERISE THE GENOMIC DNA (GDNA) YIELD FROM URINE AND QUALITY OF DERIVED METHYLATION DATA GENERATED FROM THE WIDELY USED ILLUMINIA INFINIUM METHYLATIONEPIC (HM850K) PLATFORM AND COMPARE THIS WITH BUFFY COAT SAMPLES. BACKGROUND: DNA METHYLATION IS THE MOST WIDELY STUDIED EPIGENETIC MARK AND VARIATIONS IN DNA METHYLATION PROFILE HAVE BEEN IMPLICATED IN DIABETES WHICH AFFECTS APPROXIMATELY 415 MILLION PEOPLE WORLDWIDE. METHODS: QIAAMP VIRAL RNA MINI KIT AND QIAAMP DNA MICRO KIT WERE USED TO EXTRACT DNA FROM FROZEN AND FRESH URINE SAMPLES AS WELL AS INCREASING VOLUMES OF FRESH URINE. MATCHED BUFFY COATS TO THE FROZEN URINE WERE ALSO OBTAINED AND DNA WAS EXTRACTED FROM THE BUFFY COATS USING THE QIAAMP DNA MINI KIT. GENOMIC DNA OF GREATER CONCENTRATION THAN 20MUG/ML WERE USED FOR METHYLATION ANALYSIS USING THE HM850K ARRAY. RESULTS: IRRESPECTIVE OF EXTRACTION TECHNIQUE OR THE USE OF FRESH VERSUS FROZEN URINE SAMPLES, LIMITED GENOMIC DNA WAS OBTAINED USING A STARTING SAMPLE VOLUME OF 5ML (0-0.86MUG/ML). IN ORDER TO OPTIMIZE THE YIELD, WE INCREASED STARTING VOLUMES TO 50ML FRESH URINE, WHICH YIELDED ONLY 0-9.66MUG/ML A DIFFERENT KIT, QIAAMP DNA MICRO KIT, WAS TRIALLED IN SIX FRESH URINE SAMPLES AND TEN FROZEN URINE SAMPLES WITH INADEQUATE DNA YIELDS FROM 0-17.7MUG/ML AND 0-1.6MUG/ML RESPECTIVELY. SUFFICIENT GENOMIC DNA WAS OBTAINED FROM ONLY 4 OF THE INITIAL 41 FROZEN URINE SAMPLES (10%) FOR DNA METHYLATION PROFILING. IN COMPARISON, ALL FOUR BUFFY COAT SAMPLES (100%) PROVIDED SUFFICIENT GENOMIC DNA. CONCLUSION: HIGH QUALITY DATA CAN BE OBTAINED PROVIDED A SUFFICIENT YIELD OF GENOMIC DNA IS ISOLATED. DESPITE OPTIMIZING VARIOUS EXTRACTION METHODOLOGIES, THE MODEST AMOUNT OF GENOMIC DNA DERIVED FROM URINE, MAY LIMIT THE GENERALISABILITY OF THIS APPROACH FOR THE IDENTIFICATION OF DNA METHYLATION BIOMARKERS OF CHRONIC DIABETIC KIDNEY DISEASE. 2018 18 3336 31 HISTONE DEACETYLASE INHIBITORS INDUCE PROTEOLYSIS OF ACTIVATED CDC42-ASSOCIATED KINASE-1 IN LEUKEMIC CELLS. PURPOSE: ACTIVATED CDC42-ASSOCIATED KINASE-1 (ACK1/TNK2) AND EPIGENETIC REGULATORS OF THE HISTONE DEACETYLASE (HDAC) FAMILY REGULATE THE PROLIFERATION AND SURVIVAL OF LEUKEMIC CELLS. 18 HDACS FALL INTO FOUR CLASSES (I-IV). WE TESTED THE IMPACT OF CLINICALLY RELEVANT HISTONE DEACETYLASE INHIBITORS (HDACI) ON ACK1 AND IF SUCH DRUGS COMBINE FAVORABLY WITH THE THERAPEUTICALLY USED ACK1 INHIBITOR DASATINIB. METHODS: WE APPLIED THE BROAD-RANGE HDACI PANOBINOSTAT/LBH589 AND THE CLASS I HDAC-SPECIFIC INHIBITOR ENTINOSTAT/MS-275 TO VARIOUS ACUTE AND CHRONIC MYELOID LEUKEMIA CELLS (AML/CML). WE ALSO USED THE REPLICATIVE STRESS INDUCER HYDROXYUREA (HU), A STANDARD DRUG FOR LEUKEMIC PATIENTS, AND THE APOPTOSIS INDUCER STAUROSPORINE (STS). TO ASSESS CYTOTOXIC EFFECTS OF HDACI, WE MEASURED CELL CYCLE PROFILES AND DNA FRAGMENTATION BY FLOW CYTOMETRY. WESTERN BLOT WAS EMPLOYED TO ANALYZE PROTEIN EXPRESSION AND PHOSPHORYLATION. RESULTS: LBH589 AND MS-275 INDUCE PROTEOLYSIS OF ACK1 IN CML AND AML CELLS. PANOBINOSTAT MORE STRONGLY INDUCES APOPTOSIS THAN ENTINOSTAT, AND THIS CORRELATES WITH A SIGNIFICANTLY PRONOUNCED LOSS OF ACK1. STS AND HU ALSO PROPEL THE DEGRADATION OF ACK1 IN LEUKEMIC CELLS. MOREOVER, THE CASPASE INHIBITOR Z-VAD-FMK REDUCES ACK1 DEGRADATION IN THE PRESENCE OF HDACI. CONCOMITANT WITH THE ATTENUATION OF ACK1, WE NOTICED DECREASED PHOSPHORYLATION OF STAT3. DIRECT INHIBITION OF ACK1 WITH DASATINIB ALSO SUPPRESSES STAT3 PHOSPHORYLATION. FURTHERMORE, DASATINIB AND HDACI COMBINATIONS ARE EFFECTIVE AGAINST CML CELLS. CONCLUSION: HDACS SUSTAIN THE ACK1-STAT3 SIGNALING NODE AND LEUKEMIC CELL GROWTH. CONSISTENT WITH THEIR DIFFERENT EFFECTS ON ACK1 STABILITY OR AUTO-PHOSPHORYLATION, DASATINIB AND HDACI COMBINATIONS PRODUCE BENEFICIAL ANTILEUKEMIC EFFECTS. 2016 19 4400 34 MODULATION OF HEPATIC STELLATE CELLS BY MUTAFLOR((R)) PROBIOTIC IN NON-ALCOHOLIC FATTY LIVER DISEASE MANAGEMENT. BACKGROUND: NAFLD AND NASH ARE EMERGING AS PRIMARY CAUSES OF CHRONIC LIVER DISEASE, INDICATING A NEED FOR AN EFFECTIVE TREATMENT. MUTAFLOR(R) PROBIOTIC, A MICROBIAL TREATMENT OF INTEREST, WAS EFFECTIVE IN SUSTAINING REMISSION IN ULCERATIVE COLITIS PATIENTS. OBJECTIVE: TO CONSTRUCT A GENETIC-EPIGENETIC NETWORK LINKED TO HSC SIGNALING AS A MODULATOR OF NAFLD/NASH PATHOGENESIS, THEN ASSESS THE EFFECTS OF MUTAFLOR((R)) ON THIS NETWORK. METHODS: FIRST, IN SILICO ANALYSIS WAS USED TO CONSTRUCT A GENETIC-EPIGENETIC NETWORK LINKED TO HSC SIGNALING. SECOND, AN INVESTIGATION USING RATS, INCLUDING HFHSD INDUCED NASH AND MUTAFLOR((R)) TREATED ANIMALS, WAS DESIGNED. EXPERIMENTAL PROCEDURES INCLUDED BIOCHEMICAL AND HISTOPATHOLOGIC ANALYSIS OF RAT BLOOD AND LIVER SAMPLES. AT THE MOLECULAR LEVEL, THE EXPRESSION OF GENETIC (FOXA2, TEAD2, AND LATS2 MRNAS) AND EPIGENETIC (MIR-650, RPARP AS-1 LNCRNA) NETWORK WAS MEASURED BY REAL-TIME PCR. PCR RESULTS WERE VALIDATED WITH IMMUNOHISTOCHEMISTRY (ALPHA-SMA AND LATS2). TARGET EFFECTOR PROTEINS, IL-6 AND TGF-BETA, WERE ESTIMATED BY ELISA. RESULTS: MUTAFLOR((R)) ADMINISTRATION MINIMIZED BIOCHEMICAL AND HISTOPATHOLOGIC ALTERATIONS CAUSED BY NAFLD/NASH. HSC ACTIVATION AND EXPRESSION OF PROFIBROGENIC IL-6 AND TGF-BETA EFFECTOR PROTEINS WERE REDUCED VIA INHIBITION OF HEDGEHOG AND HIPPO PATHWAYS. PATHWAYS MAY HAVE BEEN INHIBITED THROUGH UPREGULATION OF RPARP AS-1 LNCRNA WHICH IN TURN DOWNREGULATED THE EXPRESSION OF MIR-650, FOXA2 MRNA AND TEAD2 MRNA AND UPREGULATED LATS2 MRNA EXPRESSION. CONCLUSION: MUTAFLOR((R)) MAY SLOW THE PROGRESSION OF NAFLD/NASH BY MODULATING A GENETIC-EPIGENETIC NETWORK LINKED TO HSC SIGNALING. THE PROBIOTIC MAY BE A USEFUL MODALITY FOR THE PREVENTION AND TREATMENT OF NAFLD/NASH. 2022 20 1471 32 DISTINCT GLOBAL DNA METHYLATION STATUS IN B-CELL LYMPHOMAS: IMMUNOHISTOCHEMICAL STUDY OF 5-METHYLCYTOSINE AND 5-HYDROXYMETHYLCYTOSINE. LYMPHOMAS ARE MALIGNANT NEOPLASMS COMPOSED OF LYMPHOID CELLS AT VARIOUS DEVELOPMENTAL STAGES AND LINEAGES. RECENT ADVANCES IN COMPREHENSIVE GENOMIC ANALYSES IN ACUTE MYELOID LEUKEMIA HAVE REVEALED PREVALENT MUTATIONS IN REGULATORS OF EPIGENETIC PHENOMENA INCLUDING GLOBAL DNA METHYLATION STATUS. THE EXAMPLES INCLUDE MUTATIONS IN ISOCITRATE DEHYDROGENASE 1 (IDH1), IDH2, AND TEN-ELEVEN TRANSLOCATION 2. THESE MUTATIONS ARE PROPOSED TO INHIBIT CONVERSION OF 5-METHYLCYTOSINE (5 MC) TO 5-HYDROXYMETHYLCYTOSINE (5 HMC), LEADING TO GLOBAL ACCUMULATION OF 5 MC. THESE CHANGES IN GLOBAL DNA METHYLATION STATUS CAN BE VISUALIZED IMMUNOHISTOCHEMICALLY USING SPECIFIC ANTIBODIES AGAINST 5 MC AND 5 HMC. WE EXAMINED THE GLOBAL DNA METHYLATION STATUS OF B-CELL LYMPHOMAS AND THAT OF THEIR NORMAL COUNTERPARTS BY IMMUNOHISTOCHEMISTRY FOR 5 MC AND 5 HMC. NON-TUMOR LYMPHOID CELLS INSIDE GERMINAL CENTERS (GC) IN REACTIVE LYMPHOID HYPERPLASIA (RLH) WERE STAINED POSITIVE FOR 5 MC, BUT THEY WERE NEGATIVE FOR 5 HMC. SIMILARLY, FOLLICULAR LYMPHOMAS, WHOSE POSTULATED NORMAL COUNTERPARTS ARE CENTROCYTES IN GCS, WERE 5 MC-POSITIVE BUT 5 HMC-NEGATIVE BY IMMUNOHISTOCHEMISTRY. THIS IMMUNOSTAINING PATTERN WAS ALSO OBSERVED IN BURKITT LYMPHOMA. IN CONTRAST, NON-TUMOR LYMPHOID CELLS IN MANTLE ZONES WERE STAINED POSITIVE FOR 5 MC AS WELL AS FOR 5 HMC. LIKEWISE, MOST MANTLE CELL LYMPHOMAS, WHOSE POSTULATED NORMAL COUNTERPARTS ARE MANTLE ZONE B CELLS IN RLH, WERE STAINED POSITIVE FOR 5 MC AS WELL AS FOR 5 HMC. THIS IMMUNOSTAINING PATTERN WAS ALSO OBSERVED IN CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. THESE RESULTS SUGGEST THAT, IN TERMS OF 5 MC/5 HMC IMMUNOHISTOCHEMISTRY, B-CELL LYMPHOMAS WITH DIFFERENT HISTOLOGICAL SUBTYPES ARE ASSOCIATED WITH DISTINCT GLOBAL DNA METHYLATION STATUSES THAT RESEMBLE THOSE OF THEIR POSTULATED NORMAL COUNTERPARTS. 2014